PD-L1 positive cancer

1 trials 1 recruiting MedDRA PT
1 Registered trials
1 Recruiting
1 Unique sponsors
1 Unique IMPs
0 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (immune) 1 substance
Phase III: 1

Filter these 1 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 1 trials

Phase III

1 trial
  • ETOP IBCSG Partners Foundation Academic
    CEMIPLIMAB
    2024-519901-36-00 7 countries 2025 n=300
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
ETOP IBCSG Partners Foundation Academic 1 Phase III 1
New trials by year
2025
1
← All indication landscapes